Antimalarial Compounds for Blocking Sporozoite Liver Invasion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Plasmodium falciparum malaria lack effective methods to block sporozoite invasion and subsequent liver-stage parasite development, which is crucial for preventing the deadliest form of malaria.
Innovation Solution
Development of compounds, such as friomaramide, isolated from Antarctic sponge Inflatella coelosphaeroides, which are formulated into pharmaceutical preparations to inhibit sporozoite invasion and subsequent liver-stage parasite development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Plasmodium falciparum malaria are used, then existing therapeutic options are available, but they lack effective methods to block sporozoite invasion and subsequent liver-stage parasite development
Solution Approach 1:
The patent extracts and isolates friomaramide, a specific bioactive compound, from the Antarctic sponge Inflatella coelosphaeroides. This extraction process identifies and separates the active anti-malarial component from the natural source, creating a concentrated therapeutic agent that specifically targets sporozoite invasion and liver-stage development, thereby resolving the limitation of current treatments lacking effective blocking methods
Solution Approach 2:
The patent changes the chemical parameter space by introducing a novel compound with unique molecular structure and properties. Friomaramide exhibits distinct chemical characteristics that enable it to effectively block sporozoite invasion and liver-stage development, representing a significant parameter change from existing treatments and providing the desired therapeutic effectiveness
2Reliability
If compounds are developed to inhibit sporozoite invasion and liver-stage parasite development, then therapeutic effectiveness is improved, but toxicity to human hepatocytes must be avoided
Solution Approach 1:
The patent applies local quality by designing a compound that exhibits selective activity - friomaramide demonstrates high anti-malarial effectiveness against liver-stage parasites while simultaneously maintaining low toxicity to human hepatocytes. This selective local action at the parasite interface, rather than broad-spectrum toxicity, resolves the contradiction between therapeutic effectiveness and safety
Solution Approach 2:
The patent converts the potential harm of anti-malarial compounds (hepatotoxicity) into benefit by identifying and characterizing friomaramide's unique property of selective anti-parasitic activity. The compound's molecular structure and biochemical properties are such that it targets parasite-specific pathways while sparing human liver cells, effectively converting the potential harmful effect into a beneficial selective therapeutic profile
Data Source
AI summary
Described herein are compounds, formulations, and methods for blocking sporozoite invasion and subsequent liver-stage parasite development of a protozoan parasite, such as Plasmodium falciparum.